This is the authors' abstract. We don't add key points for this paper.
Aims Vancomycin, an antibiotic, is used to treat infection of multi-drug resistant strains of Clostridium difficile and Staphylococcus . Post-usage effects of vancomycin may lead to many unwanted effects including perturbation of gut microbiota. Perturbation of the gut microbiota, by Vancomycin, was used to understand the altered metabolic and innate immune profile of C57BL/6(Th1-biased) and BALB/c (Th2-biased) mice. Methods and Results Following treatment with vancomycin till day 4, we observed reduction in abundance of phyla Firmicutes and Bacteroides and increase in Proteobacteria in the gut for both strains of mice. Results further revealed a significant increase in the phylum Verrucomicrobia, from day 5 onwards following treatment with vancomycin led to decreased inflammation and increased rate of glucose tolerance in the host. Conclusions Continued dosage of vancomycin was more beneficial in C57BL/6 than BALB/c mice Significance and Impact of the study The current study established that initial doses of vancomycin increased pathogenic bacteria but the continued doses of vancomycin provided significant health-related benefits to the host by decreasing pathogenic load and by increasing beneficial microbes of Verrucomicrobia phylum ( A. muciniphila ) more in C57BL/6 (Th-1) than BALB/c (Th-2) mice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ray et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: